Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen

Vaccine

Volumn 27, Issue 33, 2009, Pages 4475-4482

  Hodge, James W ^a   Higgins, Jack ^a   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Carcinoembryonic antigen (CEA); Costimulation; Modified vaccinia Ankara (MVA); Vaccinia

Indexed keywords

B7 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY; VACCINIA VIRUS;

ANIMALS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CYTOKINES; FEMALE; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES; TIME FACTORS; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 67649340803     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.017     Document Type: Article

References (49)

1. Emens L.A. Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs 13 June (2) (2008) 295-308
2. Kreijtz J.H., Osterhaus A.D., and Rimmelzwaan G.F. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum Vaccin 5 March (3) (2009)
3. McShane H., and Hill A. Prime-boost immunisation strategies for tuberculosis. Microbes Infect 7 May (5-6) (2005) 962-967
4. Baker B.M., Block B.L., Rothchild A.C., and Walker B.D. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther 9 January (1) (2009) 55-69
5. Genton B. Malaria vaccines: a toy for travelers or a tool for eradication?. Expert Rev Vaccines 7 July (5) (2008) 597-611
6. Weide B., Garbe C., Rammensee H.G., and Pascolo S. Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunol Lett 115 January (1) (2008) 33-42
7. Wallecha A., Maciag P.C., Rivera S., Paterson Y., and Shahabi V. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin Vaccine Immunol 16 January (1) (2009) 96-103
8. Gomez C.E., Najera J.L., Krupa M., and Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 8 April (2) (2008) 97-120
9. Wansley E.K., Chakraborty M., Hance K.W., Bernstein M.B., Boehm A.L., Guo Z., et al. Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res 14 July (13) (2008) 4316-4325
10. Schlom J., Arlen P.M., and Gulley J.L. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 13 July (13) (2007) 3776-3782
11. Hodge J.W., Poole D.J., Aarts W.M., Gomez Yafal A., Gritz L., and Schlom J. Modified vaccinia virus Ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res 63 November (22) (2003) 7942-7949
12. Amato R.J., Drury N., Naylor S., Jac J., Saxena S., Cao A., et al. Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax), a phase 2 trial. J Immunother 31 July-August (6) (2008) 577-585
13. Amato R.J., Shingler W., Naylor S., Jac J., Willis J., Saxena S., et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial. Clin Cancer Res 14 November (22) (2008) 7504-7510
14. Ramlau R., Quoix E., Rolski J., Pless M., Lena H., Levy E., et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol 3 July (7) (2008) 735-744
15. Song G.Y., Gibson G., Haq W., Huang E.C., Srivasta T., Hollstein M., et al. An MVA vaccine overcomes tolerance to human p53 in mice and humans. Cancer Immunol Immunother 56 August (8) (2007) 1193-1205
16. Sharpe S., Polyanskaya N., Dennis M., Sutter G., Hanke T., Erfle V., et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J Gen Virol 82 September (Pt 9) (2001) 2215-2223
17. Grandpre L.E., Duke-Cohan J.S., Ewald B.A., Devoy C., Barouch D.H., Letvin N.L., et al. Immunogenicity of recombinant modified vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys. Vaccine 27 March (10) (2009) 1549-1556
18. Hodge J.W., McLaughlin J.P., Kantor J.A., and Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15 April-May (6-7) (1997) 759-768
19. Marshall J.L., Hoyer R.J., Toomey M.A., Faraguna K., Chang P., Richmond E., et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 18 December (23) (2000) 3964-3973
20. Irvine K.R., Chamberlain R.S., Shulman E.P., Surman D.R., Rosenberg S.A., and Restifo N.P. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 89 November (21) (1997) 1595-1601
21. Vazquez-Blomquist D., Quintana D., and Duarte C.A. Modified-vaccinia-virus-Ankara (MVA) priming and fowlpox-virus booster elicit a stronger CD8+ T-cell response in mice against an HIV-1 epitope than does a DNA/poxvirus prime-booster approach. Biotechnol Appl Biochem 39 June (Pt 3) (2004) 313-318
22. Liu L., Chavan R., and Feinberg M.B. Dendritic cells are preferentially targeted among hematolymphocytes by modified vaccinia virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol 9 (2008) 15
23. Gasteiger G., Kastenmuller W., Ljapoci R., Sutter G., and Drexler I. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol 81 November (21) (2007) 11925-11936
24. Samuelsson C., Hausmann J., Lauterbach H., Schmidt M., Akira S., Wagner H., et al. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest 118 May (5) (2008) 1776-1784
25. Waibler Z., Anzaghe M., Ludwig H., Akira S., Weiss S., Sutter G., et al. Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J Virol 81 November (22) (2007) 12102-12110
26. Hodge J.W., Rad A.N., Grosenbach D.W., Sabzevari H., Yafal A.G., Gritz L., et al. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst 92 August (15) (2000) 1228-1239
27. Kass E., Panicali D.L., Mazzara G., Schlom J., and Greiner J.W. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 61 January (1) (2001) 206-214
28. Yang S., Hodge J.W., Grosenbach D.W., and Schlom J. Vaccines with enhanced costimulation maintain high avidity memory CTL. J Immunol 175 September (6) (2005) 3715-3723
29. Eades-Perner A.M., van der Putten H., Hirth A., Thompson J., Neumaier M., von Kleist S., et al. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res 54 August (15) (1994) 4169-4176
30. Robbins P.F., Kantor J.A., Salgaller M., Hand P.H., Fernsten P.D., and Schlom J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 51 July (14) (1991) 3657-3662
31. Schmitz J., Reali E., Hodge J.W., Patel A., Davis G., Schlom J., et al. Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8 (+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res 62 September (17) (2002) 5058-5064
32. Esquivel F., Yewdell J., and Bennink J. RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes. J Exp Med 175 January (1) (1992) 163-168
33. Lehmann M.H., Kastenmuller W., Kandemir J.D., Brandt F., Suezer Y., and Sutter G. Modified vaccinia virus Ankara (MVA) triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J Virol 83 March (6) (2009) 2540-2552
34. Drillien R., Spehner D., and Hanau D. Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J Gen Virol 85 August (Pt 8) (2004) 2167-2175
35. Vilsmeier B. Paramunity-inducing effects of vaccinia strain MVA. Berl Munch Tierarztl Wochenschr 112 September (9) (1999) 329-333
36. Sutter G., and Moss B. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev Biol Stand 84 (1995) 195-200
37. Moss B., Carroll M.W., Wyatt L.S., Bennink J.R., Hirsch V.M., Goldstein S., et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 397 (1996) 7-13
38. Parrino J., McCurdy L.H., Larkin B.D., Gordon I.J., Rucker S.E., Enama M.E., et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 25 February (8) (2007) 1513-1525
39. Vollmar J., Arndtz N., Eckl K.M., Thomsen T., Petzold B., Mateo L., et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24 March (12) (2006) 2065-2070
40. Engelmayer J., Larsson M., Subklewe M., Chahroudi A., Cox W.I., Steinman R.M., et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol 163 December (12) (1999) 6762-6768
41. Chahroudi A., Garber D.A., Reeves P., Liu L., Kalman D., and Feinberg M.B. Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. J Virol 80 September (17) (2006) 8469-8481
42. Blanchard T.J., Alcami A., Andrea P., and Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79 May (Pt 5) (1998) 1159-1167
43. Cicinnati V.R., Kang J., Hou J., Lindemann M., Koop K., Tuting T., et al. Interferon-alpha differentially affects homeostasis of human plasmacytoid and myeloid dendritic cells. J Interferon Cytokine Res 29 March (3) (2009) 146-160
44. Young J.W., Merad M., and Hart D.N. Dendritic cells in transplantation and immune-based therapies. Biol Blood Marrow Transplant 13 January (1 Suppl. 1) (2007) 23-32
45. Dreicer R., Stadler W.M., Ahmann F.R., Whiteside T., Bizouarne N., Acres B., et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs October (2008) (Epub ahead of print)
46. Harrop R., Drury N., Shingler W., Chikoti P., Redchenko I., Carroll M.W., et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 13 August (15 Pt 1) (2007) 4487-4494
47. Oxford Biomedica Announces Data Safety Monitoring Board Recommendation for TROVAX Phase III TRIST Study; 2008. Available from: http://www.oxfordbiomedica.co.uk/news/2008-ob-21.asp [cited February 2009].
48. Hodge J.W., Grosenbach D.W., Aarts W.M., Poole D.J., and Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res 9 May (5) (2003) 1837-1849
49. Hodge J.W., Chakraborty M., Kudo-Saito C., Garnett C.T., and Schlom J. Multiple costimulatory modalities enhance CTL avidity. J Immunol 174 May (10) (2005) 5994-6004